News & Resources

Overview

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$0.41
Change (%) Stock is Down 0.02 (4.65%)
Volume663,050
May 26, 2016 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
05/26/16Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
05/23/16Orexigen Appoints New Member of Board of Directors and Announces Senior Management ChangesPrinter Friendly Version
05/04/16Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016Printer Friendly Version
05/03/16Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and DevelopmentPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.